The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
Abstract
This study aimed to characterize possible relationships between polymorphisms in the drug transporter genes organic anion transporting polypeptide-C (OATP-C, SLCO1B1), OATP-B (SLCO2B1), multidrug resistance-associated protein 2 (MRP2, ABCC2) and multidrug resistance transporter (MDR1, ABCB1) and the pharmacokinetics of pravastatin. We studied 41 healthy Caucasian volunteers who had previously participated in pharmacokinetic studies with pravastatin. Six volunteers had a very high pravastatin AUC value and were defined as outliers according to statistical criteria. The OATP-C gene was sequenced completely in all subjects, and they were also genotyped for selected single nucleotide polymorphisms (SNP) in the OATP-B, MDR1 and MRP2 genes. Of the six outliers, five were heterozygous for the OATP-C 521T>C (Val174Ala) SNP (allele frequency 42%) and three were heterozygous for a new SNP in the promoter region of OATP-C (-11187G>A, allele frequency 25%). Among the remaining 35 subjects, two were homozygous and six were heterozygous carriers of the 521T>C SNP (allele frequency 14%, P = 0.0384 versus outliers) and three were heterozygous carriers of the -11187G>A SNP (allele frequency 4%, P = 0.0380 versus outliers). In subjects with the -11187GA or 521TC genotype, the mean pravastatin AUC0-12 was 98% (P = 0.0061) or 106% (P = 0.0034) higher, respectively, compared to subjects with the reference genotype. These results were substantiated by haplotype analysis. In heterozygous carriers of *15B (containing the 388A>G and 521T>C variants), the mean pravastatin AUC0-12 was 93% (P = 0.024) higher compared to non-carriers and, in heterozygous carriers of *17 (containing the -11187G>A, 388A>G and 521T>C variants), it was 130% (P = 0.0053) higher compared to non-carriers. No significant associations were found between OATP-B, MRP2 or MDR1 polymorphisms and the pharmacokinetics of pravastatin. These results suggest that haplotypes are more informative in predicting the OATP-C phenotype than single SNPs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Statistical Method for Haplotype Reconstruction from Population Data
Stephens, M., Smith, N. J., & Donnelly, P. (2001) · The American Journal of Human Genetics · doi:10.1086/319501 · Cited by 7,493
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
Self-citationThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Identification of functionally variant MDR1 alleles among European Americans and African Americans
Kim, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117412 · Cited by 1,009
Nickerson, D. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.14.2745 · Cited by 931
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
König, J., Nies, A. T., Cui, Y., Leier, I., & Keppler, D. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00169-8 · Cited by 791
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Molecular Basis of Ethnic Differences in Drug Disposition and Response
Xie, H.-G., Kim, R. B., Wood, A. J., & Stein, C. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.815 · Cited by 600
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Rieder, M. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.4.967 · Cited by 506
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
Kirn, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., et al. (1999) · Pharmaceutical Research · doi:10.1023/a:1018877803319 · Cited by 454
Self-citationKroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00006 · Cited by 429
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 423
Kobayashi, D., Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051300 · Cited by 416
Olkkola, K. T., Backman, J. T., & Neuvonen, P. J. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.60 · Cited by 409
Self-citationNeuvonen, P. J., Kantola, T., & Kivistö, K. T. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90165-5 · Cited by 406
Self-citationShitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
Tirona, R. G., Leake, B. F., Wolkoff, A. W., & Kim, R. B. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.043026 · Cited by 324
Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J.-I., Sai, Y., Tsuji, A., & Yokoi, T. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.2.804 · Cited by 318
Genetic Polymorphisms of the Human MDR1 Drug Transporter
Schwab, M., Eichelbaum, M., & Fromm, M. F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 308
Self-citationModulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene
Johne, A., Köpke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M. F., Brinkmann, U., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129196 · Cited by 306
Self-citationFrequency of C3435T polymorphism of MDR1 gene in African people
Schaeffeler, E., Eichelbaum, M. F., Brinkmann, U., Penger, A., Asante-Poku, S., Zanger, U. M., & Schwab, M. G. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05579-9 · Cited by 281
Self-citationGrapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
LILJA, J., KIVISTO, K., & NEUVONEN, P. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)90048-6 · Cited by 241
Self-citationClinical Pharmacokinetics of Pravastatin: Mechanisms of Pharmacokinetic Events
Hatanaka, T. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039060-00002 · Cited by 224
Nakai, D., Nakagomi, R., Furuta, Y., Tokui, T., Abe, T., Ikeda, T., & Nishimura, K. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29609-9 · Cited by 217
Suzuki, H., & Sugiyama, Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00075-3 · Cited by 211
Wu, X., Whitfield, L. R., & Stewart, B. H. (2000) · Pharmaceutical Research · doi:10.1023/a:1007525616017 · Cited by 189
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
Kyrklund, C. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00052-3 · Cited by 189
Self-citationSinghvi, S., Pan, H., Morrison, R., & Willard, D. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03626.x · Cited by 179
Chen, Z.-S., Kawabe, T., Ono, M., Aoki, S., Sumizawa, T., Furukawa, T., Uchiumi, T., Wada, M., Kuwano, M., & Akiyama, S.-I. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.6.1219 · Cited by 178
Furuno, T., Landi, M.-T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00004 · Cited by 178
Self-citationTranson, C., Leemann, T., & Dayer, P. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050094 · Cited by 173
Tamai, I., & Safa, A. R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46252-1 · Cited by 166
Back, D., & Tjia, J. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03963.x · Cited by 163
Jurima-Romet, M., Crawford, K., Cyr, T., & Inaba, T. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08427-2 · Cited by 163
Kimchi‐Sarfaty, C., Gribar, J. J., & Gottesman, M. M. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.1 · Cited by 156
Michalski, C. W., Cui, Y., Nies, A. T., Nussler, A. K., Neuhaus, P., Zanger, U. M., Klein, K., Eichelbaum, M. F., KEPPLER, D. O. R., & König, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207735200 · Cited by 140
Self-citationYamazaki, M., Akiyama, S., Ni'inuma, K., Nishigaki, R., & Sugiyama, Y. (1997) · PubMed · doi:10.7270/q2cr5vmx · Cited by 140
Jacobsen, W., Kirchner, G. I., Hallensleben, K., Mancinelli, L., Deters, M., Hackbarth, I., Benet, L. Z., Sewing, K.-F., & Christians, U. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15273-7 · Cited by 134
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations
Kantola, T., Backman, J. T., Niemi, M., Kivistö, K. T., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000127 · Cited by 122
Self-citationBack, D., Tjia, J. F., Karbwang, J., & Colbert, J. E. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03359.x · Cited by 112
Biotransformation of pravastatin sodium in humans.
Everett, D. W., Chando, T. J., DiDonato, G. C., Singhvi, S. M., Pan, H., & Weinstein, S. H. (1991) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08889-0 · Cited by 112
Wienkers, L. C., Wurden, C. J., Storch, E. M., et al. (1996) · PubMed · Cited by 111
Hedman, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.011 · Cited by 93
Nebert, D. W. (2000) · Pharmacogenetics · doi:10.1097/00008571-200006000-00001 · Cited by 92
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects
Kyrklund, C., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01972.x · Cited by 77
Self-citationPazzucconi, F., Dorigotti, F., Gianfranceschi, G., Campagnoli, G., Sirtori, M., Franceschini, G., & Sirtori, C. R. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)05571-d · Cited by 50
Jacobsen, W., Kirchner, G. I., Hallensleben, K., Mancinelli, L., Deters, M., Hackbarth, I., Baner, K., Benet, L. Z., Sewing, K., & Christians, U. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35080-3 · Cited by 46
Pharmacogenetics of hepatocellular transporters
Pauli‐Magnus, C., & Meier, P. J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200304000-00003 · Cited by 40
Gastrointestinal Absorption of Pravastatin in Healthy Subjects
Triscari, J. M., O'Donnell, D., Zinny, M. A., & Pan, H. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb05002.x · Cited by 39
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Self-citationDrug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Self-citationRoth, M., Obaidat, A., & Hagenbuch, B. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01724.x · Cited by 767
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Self-citation
Metadata
- Authors
- Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., Eichelbaum, M., & Kivistö, K. T.
- Venue
- Pharmacogenetics
- Published
- 2004-07
- Volume
- 14
- Issue
- 7
- Pages
- 429-440
- ISSN
- 0960-314X (ISSN-L)
- OpenAlex
- W2039986849
- Cited by
- 418
- References
- 52
- FWCI
- 27.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.